Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients.

•Prescription medicine coverage for hematopoietic cell transplantation for some Medicare beneficiaries, especially those with multiple post–hematopoietic cell transplantation complications, is a source of financial burden for these low-fixed-income patients•Individual and policy level changes may need to occur to provide long-term affordable care to hematopoietic cell transplantation patients to avoid poor clinical and financial outcomes